Devita, Hellman, and Rosenberg's Cancer

LWBK1006-18 LWW-Govindan-Review November 24, 2011 11:24

Chapter 18•Cancer of the Lung 207

Question 18.8. A 58-year-old man, with a 40 pack-year history of smoking is referred

to you by a radiation oncologist for management of limited-stage SCLC.

What treatment would you recommend?

A. Cisplatin and etoposide chemotherapy

B. Cisplatin and etoposide chemotherapy with concurrent thoracic radi-

ation

C. Cisplatin and etoposide chemotherapy, followed by PCI if response

to chemotherapy

D. Cisplatin and etoposide chemotherapy with concurrent thoracic radi-

ation, followed by PCI if response to treatment

Question 18.9. Which of the following statements is/are correct regarding the role of

adjuvant chemotherapy after resection for NSCLC?

A. Adjuvant chemotherapy does not appear to benefit patients with stage

IA disease.

B. Adjuvant chemotherapy benefits patients with node-positive disease.

C. Adjuvant chemotherapy may benefit patients with stage IB disease,

who have primary tumors larger than 4 cm in size.

D. All of the above.

Question 18.10. Which of the following statements is correct regarding pulmonary carci-

noid tumors?

A. Patients usually present with carcinoid syndrome.

B. Surgery has a curative potential for resectable localized tumors.

C. Adjuvant chemotherapy is the standard of care following complete

surgical resection.

D. Most pulmonary carcinoids are atypical carcinoids.

Question 18.11. Which of the following is INCORRECT regarding erlotinib for the treat-

ment of advanced NSCLC?

A. Patients with L858R mutations respond better than those with exon

19 deletions.

B. Resistance to erlotinib therapy occurs through acquisition of T790M

mutation in EGFR.

C. MET amplification in tumors can lead to resistance to erlotinib ther-

apy.

D. Presence of erlotinib-induced skin rash correlates with response to

therapy.